- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Maxum posts higher 1994 results
The restructuring of mobile imaging firm Maxum Health resulted in the Dallas-based company postinga net profit of $4.2 million for fiscal 1994 (end-December). Maxumsaid it restructured most of its debt and leasing arrangementsin 1994 and entered into a
The restructuring of mobile imaging firm Maxum Health resulted in the Dallas-based company postinga net profit of $4.2 million for fiscal 1994 (end-December). Maxumsaid it restructured most of its debt and leasing arrangementsin 1994 and entered into a long-term contract with hospital giantColumbia/HCA to run an outpatient imaging center. Maxum beganthe restructuring effort in 1993 (SCAN 3/24/93).
Maxum posted year-end revenues of $45.9 million, up slightlyfrom $45.1 million the year before. The company's net income of$4.2 million represented a major turnaround from the $6.8 millionnet loss recorded in 1993. Much of Maxum's improvement in profitabilitywas attributable to several extraordinary gains, including $3.3million related to extinguishment of debt and $5 million for thesale of its lithotripsy partnership interests. The firm's operatingloss for 1994 stood at $2.8 million, compared to a $6 millionoperating loss in 1993.
Maxum earlier this year partnered with Columbia/HCA to purchaseArlington Diagnostic and Imaging Center in Arlington, VA. Thecenter is jointly owned by the two companies, with Maxum responsiblefor staffing and management.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.
